Biotechnology - Janssen Biotech

Filter

Current filters:

Janssen Biotech

Popular Filters

Geron in up to $935 million deal with Janssen for imetelstat

Geron in up to $935 million deal with Janssen for imetelstat

14-11-2014

Geron Corp has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech,…

BiotechnologyGeron CorpGlobalHematologyimetelstatJanssen BiotechJohnson & JohnsonLicensingOncology

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

17-10-2014

Privately-held US cancer immunotherapy developer Aduro BioTech has entered into its second agreement…

Aduro BioTechBiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingOncologyResearch

Celltrion files for US FDA approval of Remsima biosimilar

Celltrion files for US FDA approval of Remsima biosimilar

13-08-2014

South Korean biopharmaceutical firm Celltrion says it has completed the filing procedure to obtain US…

BiosimilarsBiotechnologyCellTrionClinical researchInflammatory diseasesinfliximabJanssen BiotechJohnson & JohnsonPatentsRegulationRemicadeRemsimaUSA

EMA’s CHMP backs approval of two new treatment options for rare cancers

EMA’s CHMP backs approval of two new treatment options for rare cancers

26-07-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use, at its July meeting,…

BiotechnologyEuropeFinancialGilead SciencesImbruvicaJanssen BiotechJohnson & JohnsonOncologyRegulationZydelig

ASCO 2014: latest news on lapatinib and trastuzumab, and ibrutinib

ASCO 2014: latest news on lapatinib and trastuzumab, and ibrutinib

01-06-2014

There was more important news on investigational oncology products presented at the 2014 Annual Meeting…

BiotechnologyGlaxoSmithKlineibrutinibJanssen BiotechJohnson & JohnsonLapatinibOncologyPharmacyclicsResearchtrastuzumab

Pharmacyclics seeks additional indication for Imbruvica in USA

Pharmacyclics seeks additional indication for Imbruvica in USA

08-04-2014

USA-based Pharmacyclics has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug…

BiotechnologyImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmacyclicsRegulationUSA

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

30-01-2014

Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen…

BiotechnologyDermatologicalsJanssen BiotechMarkets & MarketingStelara InjectionUSA

Capricor Therapeutics and Janssen collaborate on cell therapy program

Capricor Therapeutics and Janssen collaborate on cell therapy program

07-01-2014

California, USA-based Capricor Therapeutics says it has executed a collaboration agreement and exclusive…

BiotechnologyCAP-1002Capricor TherapeuticsCardio-vascularJanssen BiotechJohnson & JohnsonLicensing

Janssen in-licenses rights to novel cancer therapy from CSL

Janssen in-licenses rights to novel cancer therapy from CSL

05-12-2013

Australian blood products and vaccine maker CSL Ltd has entered into an agreement with Janssen Biotech,…

BiotechnologyCSL LimitedHematologyImmunologicalsJanssen BiotechJohnson & JohnsonLicensingOncology

Johnson & Johnson's Stelara gains FDA approval for psoriatic arthritis

24-09-2013

Janssen Research & Development announced that the US Food and Drug Administration has approved Stelara…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechNorth AmericaRegulationStelara Injection

FDA acceptance of ibrutinib NDA triggers milestone for Pharmacyclics

30-08-2013

California, USA-based Pharmacyclics (Nasdaq: PCYC) said yesterday (August 29, 2013) that the US Food…

BiotechnologyibrutinibJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

Simponi ARIA cleared by US FDA

19-07-2013

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Biotech subsidiary has received US Food…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi ARIA

Affimed does deal with Janssen, as subsidiary secures funding

15-07-2013

German's privately-owned biopharmaceutical company Affimed Therapeutics has entered into an agreement…

Affimed TherapeuticsAmphivena TherapeuticsBiotechnologyEuropeFinancialJanssen Biotech

US FDA approves Janssen's Simponi to treat ulcerative colitis

16-05-2013

The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Janssen and Genmab's daratumumab fast-tracked by US FDA

03-04-2013

Denmark-based biotech firm Genmab A/S (OMX: GEN) says that the US Food and Drug Administration has granted…

BiotechnologydaratumumabGenmabJanssen BiotechJohnson & JohnsonNorth AmericaOncologyRegulation

Janssen files BLA for IV form of Simponi for moderate-to-severe RA

20-09-2012

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Biotech has submitted a Biologics…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Genmab in collaboration with Janssen for DuoBody platform

16-07-2012

Denmark-based Genmab A/S (OMX: GEN) says it has entered into a collaboration with Janssen Biotech, a…

BiotechnologyDuoBodyGenmabJanssen BiotechJohnson & JohnsonLicensingNovartisPharmaceutical

Pharmacyclics and Janssen’s PCI-32765 set to be gold standard for its blood cancer indication

19-02-2012

Based on clinical data and the opinions of interviewed thought leaders, Pharmacyclics (Nasdaq: PCYC)…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalPharmacyclics

Another mega deal for FORMA Therapeutics

11-01-2012

Hot on the heels of its up to $815 million oncology-related deal with Boehringer Ingelheim (The Pharma…

BiotechnologyFORMA TherapeuticsJanssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalResearch

Phylogica signs deal with Johnson & Johnson unit

04-01-2012

Australian peptide drug discovery company Phylogica (ASX: PYC) has entered into a collaboration and option…

BiotechnologyFinancialJanssen BiotechJohnson & JohnsonLicensingPharmaceuticalPhylogica

Janssen files Xarelto sNDA for ACS; FDA to review Amgen’s Xgeva for CRPC

30-12-2011

US health care giant Johnson & Johnson’s (NYSE: JNJ) Janssen Research & Development, has submitted…

AmgenBayerBiotechnologyCardio-vascularJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationXareltoXgeva

Back to top